keyword
MENU ▼
Read by QxMD icon Read
search

intermediate risk prostate cancer genomic

keyword
https://www.readbyqxmd.com/read/28941923/validation-of-gemcap-as-a-dna-based-biomarker-to-predict-prostate-cancer-recurrence-after-radical-prostatectomy
#1
Hao G Nguyen, Christopher Welty, Karla Lindquist, Vy Ngo, Elizabeth Gilbert, Henrik Bengtsson, Cristina Magi-Galluzzi, Jerome Jean-Gilles, Jorge Yao, Matthew Cooperberg, Edward Messing, Eric A Klein, Peter R Carroll, Pamela L Paris
PURPOSE: We aim to validate the Genomic Evaluators of Metastatic Cancer of the Prostate (GEMCaP) as a novel copy number signature predictive for prostate cancer recurrence. MATERIALS AND METHODS: We randomly selected patients who had radical prostatectomy at the Cleveland Clinic (CC) or the University of Rochester (UR) from 2000-2005. DNA isolated from the cancer region was extracted and subjected to high resolution array comparative genomic hybridization (aCGH)...
September 20, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28941920/genomic-scores-are-independent-of-disease-volume-in-men-with-favorable-risk-prostate-cancer-implications-for-choosing-men-for-active-surveillance
#2
Yaw A Nyame, Dominic C Grimberg, Daniel J Greene, Karishma Gupta, Ganesh K Kartha, Ryan Berglund, Michael Gong, Andrew J Stephenson, Cristina Magi-Galluzzi, Eric A Klein
OBJECTIVE: To determine if disease volume at prostate biopsy correlates with genomic scores among men with favorable risk prostate cancer. METHODS: All men with NCCN very low (VLR) and low risk (LR) disease and OncotypeDx Prostate testing at our institution from 2013 to 2016 were identified. Volume of disease was characterized as percent of positive cores, number of cores with >50% involvement, largest involvement of any single core, and PSA density. Nonparametric testing was performed to compare the median genomic prostate score (GPS) and likelihood of favorable pathology (LFP) between quartiles of disease volume...
September 20, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28888753/the-role-of-gut-microbiome-in-the-pathogenesis-of-prostate-cancer-a-prospective-pilot-study
#3
David M Golombos, Abimbola Ayangbesan, Padraic O'Malley, Patrick Lewicki, LaMont Barlow, Christopher E Barbieri, Chrystal Chan, Casey DuLong, Galeb Abu-Ali, Curtis Huttenhower, Douglas S Scherr
OBJECTIVE: To elucidate potential biomarkers or mechanistic principles involved with the gut microbiota and its impact on prostate cancer pathogenesis. MATERIALS AND METHODS: A prospective case-control pilot study evaluating the gut microbiome of 20 men with either benign prostatic conditions (n = 8) or intermediate/high risk clinically localized prostate cancer (Gleason ≥4+3 cN0M0) (n = 12) undergoing care at tertiary referral center from 9/1/2015 - 3/1/2016...
September 6, 2017: Urology
https://www.readbyqxmd.com/read/28825922/risk-stratification-in-oligometastatic-prostate-cancer-where-are-we-and-what-do-we-need
#4
Alicia K Morgans, Maha Hussain
PURPOSE OF REVIEW: The oligometastatic disease state was initially described over 20 years ago as an 'intermediate' stage in metastatic cancer progression potentially amenable to curative treatment. Interest in identifying men with oligometastatic disease that may be cured has been increasing. However, whether there truly is a distinct oligometastatic state requires prospective validation, and a risk stratification system based on clinical and genomic factors is needed. RECENT FINDINGS: We reviewed the existing literature, including 11 ongoing prospective clinical trials, defining the oligometastatic state...
August 18, 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/28753811/risk-of-upgrading-and-upstaging-among-10-000-patients-with-gleason-3-4-favorable-intermediate-risk-prostate-cancer
#5
David D Yang, Brandon A Mahal, Vinayak Muralidhar, Michelle D Nezolosky, Marie E Vastola, Shelby A Labe, Ninjin Boldbaatar, Martin T King, Neil E Martin, Peter F Orio, Clair J Beard, Karen E Hoffman, Quoc-Dien Trinh, Daniel E Spratt, Felix Y Feng, Paul L Nguyen
BACKGROUND: It is unknown whether active surveillance can be safely offered to patients with Gleason 3+4 favorable intermediate-risk (FIR) prostate cancer. OBJECTIVE: To examine the incidence and predictors of upgrading and upstaging among patients with Gleason 3+4 FIR disease. DESIGN, SETTING, AND PARTICIPANTS: The study involved 10 089 patients in the National Cancer Database diagnosed from 2010 to 2012 with Gleason 3+4 disease, prostate-specific antigen (PSA) <10ng/ml, and cT1c-2a prostate cancer with <50% positive biopsy cores (PBCs) who underwent radical prostatectomy...
June 17, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28572867/prolaris-cell-cycle-progression-test-for-localized-prostate-cancer-a-health-technology-assessment
#6
(no author information available yet)
BACKGROUND: Prostate cancer is very common and many localized tumours are non-aggressive. Determining which cancers are aggressive is important for choosing the most appropriate treatment (e.g., surgery, radiation, active surveillance). Current clinical risk stratification is reliable in forecasting the prognosis of groups of men with similar clinical and pathologic characteristics, but there is residual uncertainty at the individual level. The Prolaris cell cycle progression (CCP) test, a genomic test that estimates how fast tumour cells are proliferating, could potentially be used to improve the accuracy of individual risk assessment...
2017: Ontario Health Technology Assessment Series
https://www.readbyqxmd.com/read/28528811/ability-of-a-genomic-classifier-to-predict-metastasis-and-prostate-cancer-specific-mortality-after-radiation-or-surgery-based-on-needle-biopsy-specimens
#7
Paul L Nguyen, Zaid Haddad, Ashley E Ross, Neil E Martin, Samineh Deheshi, Lucia L C Lam, Jijumon Chelliserry, Jeffrey J Tosoian, Tamara L Lotan, Daniel E Spratt, Radka S Stoyanova, Sanoj Punnen, Kaye Ong, Christine Buerki, Maria Aranes, Tyler Kolisnik, Jennifer Margrave, Kasra Yousefi, Voleak Choeurng, Elai Davicioni, Bruce J Trock, Christopher J Kane, Alan Pollack, John W Davis, Felix Y Feng, Eric A Klein
BACKGROUND: Decipher is a validated genomic classifier developed to determine the biological potential for metastasis after radical prostatectomy (RP). OBJECTIVE: To evaluate the ability of biopsy Decipher to predict metastasis and Prostate cancer-specific mortality (PCSM) in primarily intermediate- to high-risk patients treated with RP or radiation therapy (RT). DESIGN, SETTING, AND PARTICIPANTS: Two hundred and thirty-five patients treated with either RP (n=105) or RT±androgen deprivation therapy (n=130) with available genomic expression profiles generated from diagnostic biopsy specimens from seven tertiary referral centers...
May 18, 2017: European Urology
https://www.readbyqxmd.com/read/28400167/validation-of-a-genomic-risk-classifier-to-predict-prostate-cancer-specific-mortality-in-men-with-adverse-pathologic-features
#8
R Jeffrey Karnes, Voleak Choeurng, Ashley E Ross, Edward M Schaeffer, Eric A Klein, Stephen J Freedland, Nicholas Erho, Kasra Yousefi, Mandeep Takhar, Elai Davicioni, Matthew R Cooperberg, Bruce J Trock
BACKGROUND: Risk of prostate cancer-specific mortality (PCSM) is highly variable for men with adverse pathologic features at radical prostatectomy (RP); a majority will die of other causes. Accurately stratifying PCSM risk can improve therapy decisions. OBJECTIVE: Validate the 22 gene Decipher genomic classifier (GC) to predict PCSM in men with adverse pathologic features after RP. DESIGN, SETTING, AND PARTICIPANTS: Men with adverse pathologic features: pT3, pN1, positive margins, or Gleason score >7 who underwent RP in 1987-2010 at Johns Hopkins, Cleveland Clinic, Mayo Clinic, and Durham Veteran's Affairs Hospital...
April 8, 2017: European Urology
https://www.readbyqxmd.com/read/28376608/decision-making-tools-in-prostate-cancer-from-risk-grouping-to-nomograms
#9
Paolo Fontanella, Luigi Benecchi, Angelica Grasso, Vipul Patel, David Albala, Claude Abbou, Francesco Porpiglia, Marco Sandri, Bernardo Rocco, Giampaolo Bianchi
INTRODUCTION: Prostate cancer (PCa) is the most common solid neoplasm and the second leading cause of cancer death in men. After the Partin tables were developed, a number of predictive and prognostic tools became available for risk stratification. These tools have allowed the urologist to better characterize this disease and lead to more confident treatment decisions for patients. The purpose of this study is to critically review the decision-making tools currently available to the Urologist, from the moment when PCa is first diagnosed until patients experience metastatic progression and death...
March 30, 2017: Minerva Urologica e Nefrologica, the Italian Journal of Urology and Nephrology
https://www.readbyqxmd.com/read/28358655/individual-patient-level-meta-analysis-of-the-performance-of-the-decipher-genomic-classifier-in-high-risk-men-after-prostatectomy-to-predict-development-of-metastatic-disease
#10
REVIEW
Daniel E Spratt, Kasra Yousefi, Samineh Deheshi, Ashley E Ross, Robert B Den, Edward M Schaeffer, Bruce J Trock, Jingbin Zhang, Andrew G Glass, Adam P Dicker, Firas Abdollah, Shuang G Zhao, Lucia L C Lam, Marguerite du Plessis, Voleak Choeurng, Zaid Haddad, Christine Buerki, Elai Davicioni, Sheila Weinmann, Stephen J Freedland, Eric A Klein, R Jeffrey Karnes, Felix Y Feng
Purpose To perform the first meta-analysis of the performance of the genomic classifier test, Decipher, in men with prostate cancer postprostatectomy. Methods MEDLINE, EMBASE, and the Decipher genomic resource information database were searched for published reports between 2011 and 2016 of men treated by prostatectomy that assessed the benefit of the Decipher test. Multivariable Cox proportional hazards models fit to individual patient data were performed; meta-analyses were conducted by pooling the study-specific hazard ratios (HRs) using random-effects modeling...
June 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28330676/stromal-gene-expression-is-predictive-for-metastatic-primary-prostate-cancer
#11
Fan Mo, Dong Lin, Mandeep Takhar, Varune Rohan Ramnarine, Xin Dong, Robert H Bell, Stanislav V Volik, Kendric Wang, Hui Xue, Yuwei Wang, Anne Haegert, Shawn Anderson, Sonal Brahmbhatt, Nicholas Erho, Xinya Wang, Peter W Gout, James Morris, R Jeffrey Karnes, Robert B Den, Eric A Klein, Edward M Schaeffer, Ashley Ross, Shancheng Ren, S Cenk Sahinalp, Yingrui Li, Xun Xu, Jun Wang, Jian Wang, Martin E Gleave, Elai Davicioni, Yinghao Sun, Yuzhuo Wang, Colin C Collins
BACKGROUND: Clinical grading systems using clinical features alongside nomograms lack precision in guiding treatment decisions in prostate cancer (PCa). There is a critical need for identification of biomarkers that can more accurately stratify patients with primary PCa. OBJECTIVE: To identify a robust prognostic signature to better distinguish indolent from aggressive prostate cancer (PCa). DESIGN, SETTING, AND PARTICIPANTS: To develop the signature, whole-genome and whole-transcriptome sequencing was conducted on five PCa patient-derived xenograft (PDX) models collected from independent foci of a single primary tumor and exhibiting variable metastatic phenotypes...
March 19, 2017: European Urology
https://www.readbyqxmd.com/read/28202223/filtration-based-enrichment-of-circulating-tumor-cells-from-all-prostate-cancer-risk-groups
#12
Julius Adebayo Awe, Jeff Saranchuk, Darrel Drachenberg, Sabine Mai
OBJECTIVE: To combine circulating tumor cell (CTC) isolation by filtration and immunohistochemistry to investigate the presence of CTCs in low, intermediate, and high-risk prostate cancer (PCa). CTCs isolated from these risk groups stained positive for both cytokeratin and androgen receptors, but negative for CD45. PATIENTS AND METHODS: Blood samples from 41 biopsy confirmed patients with PCa at different clinical stages such as low, intermediate, and high risk were analyzed...
May 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28148485/prostate-cancer-recurrence-genomic-clues
#13
(no author information available yet)
In the largest genomic analysis of intermediate-risk prostate cancer samples to date, researchers have uncovered a five-element molecular signature that could help pinpoint patients whose disease is likely to recur and metastasize even after surgery or radiotherapy. They hope to develop a prognostic assay from this signature that can be used in the clinic.
February 1, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28117383/utilization-of-biopsy-based-genomic-classifier-to-predict-distant-metastasis-after-definitive-radiation-and-short-course-adt-for-intermediate-and-high-risk-prostate-cancer
#14
P L Nguyen, N E Martin, V Choeurng, B Palmer-Aronsten, T Kolisnik, C J Beard, P F Orio, M D Nezolosky, Y-W Chen, H Shin, E Davicioni, F Y Feng
BACKGROUND: We examined the ability of a biopsy-based 22-marker genomic classifier (GC) to predict for distant metastases after radiation and a median of 6 months of androgen deprivation therapy (ADT). METHODS: We studied 100 patients with intermediate-risk (55%) and high-risk (45%) prostate cancer who received definitive radiation plus a median of 6 months of ADT (range 3-39 months) from 2001-2013 at a single center and had available biopsy tissue. Six to ten 4 micron sections of the needle biopsy core with the highest Gleason score and percentage of tumor involvement were macrodissected for RNA extraction...
June 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28024937/curative-brachytherapy-for-prostate-cancer-in-african-caribbean-patients-a-retrospective-analysis-of-370-consecutive-cases
#15
V Atallah, N Leduc, M Creoff, P Sargos, T Taouil, P Escarmant, V Vinh-Hung
PURPOSE: Prostate cancer is the most frequent malignancy in African-Caribbean men, a population sharing common genetic traits with African-American (AA) but presenting also genomic and epidemiologic specificities. Despite socioeconomic disparities with French mainland, all patients were treated within the French state-financed equal-access health care system. In this study, we report biochemical outcomes of patients treated by brachytherapy in our department from 2005 to 2014 in an African-Caribbean population...
March 2017: Brachytherapy
https://www.readbyqxmd.com/read/27987030/improved-decision-making-in-intermediate-risk-prostate-cancer-a-multicenter-study-on-pathologic-and-oncologic-outcomes-after-radical-prostatectomy
#16
Jean Baptiste Beauval, Guillaume Ploussard, Bastien Cabarrou, Mathieu Roumiguié, Adil Ouzzane, Jérome Gas, Annabelle Goujon, Gautier Marcq, Romain Mathieu, Sébastien Vincendeau, Xavier Cathelineau, Pierre Mongiat-Artus, Laurent Salomon, Michel Soulié, Arnaud Méjean, Alexandre de La Taille, Morgan Rouprêt, François Rozet
BACKGROUND: Prognoses for intermediate-risk prostate cancer (PCa) remain heterogeneous. Improved substratification could optimize treatment and monitoring strategies. The objective was to validate this subclassification in a radical prostatectomy (RP) series. METHODS: Between 2000 and 2011, 4038 patients who underwent RP for intermediate-risk PCa in seven French academic centers were included. Unfavorable intermediate-risk (UIR) PCa was defined as having a primary Gleason score of 4, ≥50% positive biopsy cores (PPBC), or more than one D'Amico intermediate-risk factor (i...
August 2017: World Journal of Urology
https://www.readbyqxmd.com/read/27746147/what-is-the-best-way-not-to-treat-prostate-cancer
#17
REVIEW
Michael S Leapman, Peter R Carroll
INTRODUCTION: Selective treatment approaches for prostate cancer (PCa) are warranted given the highly varied nature of the disease and the consequences associated with definitive therapy. MATERIALS AND METHODS: We present a stepwise overview of strategies optimized to not treat PCa, ranging from improved screening practices that seek to maximize the yield at initial diagnosis, as well as refinements to clinical risk prediction and the performance of active surveillance...
February 2017: Urologic Oncology
https://www.readbyqxmd.com/read/27725639/oligometastatic-prostate-cancer-definitions-clinical-outcomes-and-treatment-considerations
#18
REVIEW
Jeffrey J Tosoian, Michael A Gorin, Ashley E Ross, Kenneth J Pienta, Phuoc T Tran, Edward M Schaeffer
The oligometastatic state has been proposed as an intermediate stage of cancer spread between localized disease and widespread metastases. With improvements in diagnostic modalities such as functional imaging, oligometastatic prostate cancer is being diagnosed with greater frequency than ever before. Furthermore, the paradigm for treatment of advanced prostate cancers is shifting toward a more aggressive approach. Many questions surround the understanding of the process and consequences of oligometastasis, meaning that the contemporary literature offers a wide variety of definitions of oligometastatic prostate cancer...
January 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/27708722/pitx3-promoter-methylation-is-a-prognostic-biomarker-for-biochemical-recurrence-free-survival-in-prostate-cancer-patients-after-radical-prostatectomy
#19
Emily Eva Holmes, Diane Goltz, Verena Sailer, Maria Jung, Sebastian Meller, Barbara Uhl, Jörn Dietrich, Magda Röhler, Jörg Ellinger, Glen Kristiansen, Dimo Dietrich
BACKGROUND: Molecular biomarkers that might help to distinguish between more aggressive and clinically insignificant prostate cancers (PCa) are still urgently needed. Aberrant DNA methylation as a common molecular alteration in PCa seems to be a promising source for such biomarkers. In this study, PITX3 DNA methylation (mPITX3) and its potential role as a prognostic biomarker were investigated. Furthermore, mPITX3 was analyzed in combination with the established PCa methylation biomarker PITX2 (mPITX2)...
2016: Clinical Epigenetics
https://www.readbyqxmd.com/read/27675556/the-use-of-a-biopsy-based-genomic-classifier-to-predict-the-risk-of-distant-metastasis-after-definitive-radiation-and-short-course-androgen-deprivation-therapy-for-intermediate-and-high-risk-prostate-cancer
#20
P L Nguyen, N E Martin, B J Palmer-Aronsten, V Choeurng, T Kolisnik, C J Beard, M D Nezolosky, Y W Chen, H Shin, E Davicioni, F Feng
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
keyword
keyword
96307
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"